Exparel was approved by the U.S. Food and Drug Administration (FDA) on October 31, 2011 [1].
What is Exparel and what is it used for?
Exparel is an injectable non-opioid local anesthetic that provides post-operative analgesia [2]. It is used to manage moderate to moderately severe acute pain and for post-surgical pain [2]. The medication is administered by a healthcare professional [3].
How does Exparel work?
Exparel contains liposomal bupivacaine, which is a formulation of bupivacaine encased in multivesicular lipids [2]. This liposomal encapsulation allows for the extended release of bupivacaine, providing pain relief for a longer duration compared to standard bupivacaine injections [2]. It works by blocking nerve signals in the body [3].
When does Exparel's patent protection expire?
Patent information for Exparel can be tracked through resources like DrugPatentWatch.com [4]. The expiration dates for patents related to a drug determine when generic versions may enter the market.
What are the side effects of Exparel?
Common side effects of Exparel include nausea, vomiting, constipation, fever, headache, and fatigue [3]. More serious side effects can occur, and patients should discuss potential risks with their healthcare provider [3].
Who makes Exparel?
Exparel is manufactured by Pacira BioSciences, Inc. [5].